Pertuzumab

From Self-sufficiency
Jump to: navigation, search
Pertuzumab
Monoclonal antibody
Type Whole antibody
Source Template:Infobox drug/mab source
Target HER2
Identifiers
CAS Number 380610-27-5
ATC code none
Script error: No such module "TemplatePar".Expression error: Unexpected < operator.

Pertuzumab (also called 2C4, trade name Omnitarg) is a monoclonal antibody. The first of its class in a line of agents called "HER dimerization inhibitors". By binding to HER2, it inhibits the dimerization of HER2 with other HER receptors, which is hypothesized to result in slowed tumor growth.[1] Pertuzumab is currently being developed by Genentech.

Early clinical trials of pertuzumab in prostate, breast, and ovarian cancers have been met with limited success.[2]

References

  1. de Bono, Johann S.; Bellmunt, J; Attard, G; Droz, JP; Miller, K; Flechon, A; Sternberg, C; Parker, C; Zugmaier, G (20 January 2007). "Open-Label Phase II Study Evaluating the Efficacy and Safety of Two Doses of Pertuzumab in Castrate Chemotherapy-Naive Patients With Hormone-Refractory Prostate Cancer". Journal of Clinical Oncology. 25 (3): 257–262. doi:10.1200/JCO.2006.07.0888. PMID 17235043. 
  2. Genentech press release - May 15, 2005